Vaxiion begins VAX014 phase 1 trial in non-muscle invasive bladder cancer
Vaxiion Therapeutics, a clinical stage biotech company based in California, has initiated a phase 1 clinical trial of its recombinant bacterial minicell-based oncolytic immunotherapy VAX014 ... Read More